Biosimilar-to-biosimilar switching – moving patients between two different biosimilar versions of the same brand biologic – is “a safe and effective clinical practice,” a new paper published in BioDrugs has concluded, based on a review of biosimilar-to-biosimilar switching studies.
However, the paper points out that the practice “is not covered by current health authority regulations or guidance” anywhere in...